The US Centers for Disease Control & Prevention and Food & Drug Administration are taking the first big steps towards the transition in COVID vaccine delivery into more traditional channels as the Public Health Emergency phase of the pandemic winds down.
The immediate changes include moving to bivalent-only formulations of the two mRNA vaccines, Pfizer Inc./BioNTech SE’s Comirnaty and Moderna, Inc.’s Spikevax, and related changes to both the...